Literature DB >> 16189819

Reverting cholesterol auxotrophy of NS0 cells by altering epigenetic gene silencing.

Gargi Seth1, Mustafa Ozturk, Wei-Shou Hu.   

Abstract

NS0 is a cholesterol-requiring mouse myeloma cell line widely used in the production of recombinant antibodies. We have previously reported that the deficiency of 17beta-hydroxysteroid dehydrogenase type7 (Hsd17b7) is responsible for the cholesterol auxotrophy of NS0 cells. Here we demonstrate DNA methylation to be the mechanism underlying transcriptional suppression of Hsd17b7 in cholesterol dependent NS0 cells. Analysis of the DNA methylation pattern revealed methylation of the CpG-rich region upstream of the Hsd17b7 transcription start site in NS0 cells. This is in contrast to the unmethylated status of this sequence in a naturally isolated cholesterol independent revertant cell population (NS0_r). This transcriptional repression was relieved after treating cells with the demethylating drug, 5-azacytidine. Drug treatment also gave rise to high frequency cholesterol-independent variants. Characterization of revertants revealed substantially elevated transcript level of 17beta-hydroxysteroid dehydrogenase type7 (Hsd17b7) gene along with hypomethylation of the CpG-rich region. These results affirm that deficiency of Hsd17b7 causes cholesterol dependence of NS0 cells. Furthermore, induction of cholesterol independence by altering DNA methylation pattern alludes to the role of epigenetics in the metabolic adaptation of NS0 cells. With the widespread use of NS0 cells, this finding will have a significant impact on the optimization of recombinant antibody production processes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16189819     DOI: 10.1002/bit.20720

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  7 in total

Review 1.  Cell culture processes for monoclonal antibody production.

Authors:  Feng Li; Natarajan Vijayasankaran; Amy Yijuan Shen; Robert Kiss; Ashraf Amanullah
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

2.  Using cell engineering and omic tools for the improvement of cell culture processes.

Authors:  Darrin Kuystermans; Britta Krampe; Halina Swiderek; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2007-02-24       Impact factor: 2.058

3.  Toward genomic cell culture engineering.

Authors:  Katie F Wlaschin; Gargi Seth; Wei-Shou Hu
Journal:  Cytotechnology       Date:  2006-07-25       Impact factor: 2.058

4.  Divergent interactions involving the oxidosqualene cyclase and the steroid-3-ketoreductase in the sterol biosynthetic pathway of mammals and yeasts.

Authors:  Silvia Taramino; Brian Teske; Simonetta Oliaro-Bosso; Martin Bard; Gianni Balliano
Journal:  Biochim Biophys Acta       Date:  2010-07-24

5.  Cholesterol and phytosterols differentially regulate the expression of caveolin 1 and a downstream prostate cell growth-suppressor gene.

Authors:  Godwin O Ifere; Anita Equan; Kereen Gordon; Peri Nagappan; Joseph U Igietseme; Godwin A Ananaba
Journal:  Cancer Epidemiol       Date:  2010-05-12       Impact factor: 2.984

6.  Comprehensive genome and epigenome characterization of CHO cells in response to evolutionary pressures and over time.

Authors:  Julia Feichtinger; Inmaculada Hernández; Christoph Fischer; Michael Hanscho; Norbert Auer; Matthias Hackl; Vaibhav Jadhav; Martina Baumann; Peter M Krempl; Christian Schmidl; Matthias Farlik; Michael Schuster; Angelika Merkel; Andreas Sommer; Simon Heath; Daniel Rico; Christoph Bock; Gerhard G Thallinger; Nicole Borth
Journal:  Biotechnol Bioeng       Date:  2016-04-29       Impact factor: 4.530

7.  Random epigenetic modulation of CHO cells by repeated knockdown of DNA methyltransferases increases population diversity and enables sorting of cells with higher production capacities.

Authors:  Marcus Weinguny; Peter Eisenhut; Gerald Klanert; Nikolaus Virgolini; Nicolas Marx; Andreas Jonsson; Daniel Ivansson; Ann Lövgren; Nicole Borth
Journal:  Biotechnol Bioeng       Date:  2020-07-24       Impact factor: 4.395

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.